The median survival of conventionally treated patients with multiple myeloma is 3 years. Modifications of conventional chemotherapy and the administration of interferon-α have failed to show an improved survival in most randomized trials. Therapy with dose-escalated alkylating agents (i. e. melphalan 140 mg/m2) induced higher remission rates than conventional treatment. If followed by allogeneic or autologous hematopoietic progenitor cell transplantation, the hematotoxicity of the described dose-escalated treatment could be reduced. Results of transplantation trials are summarized and discussed. The transplantation of autologous peripheral blood progenitor cells results in a faster hematopoietic reconstitution and a decreased high-dose therapy-related morbidity compared to autologous bone marrow and should therefore be preferred. Although the randomized French myeloma trial showed a significant survival advantage for patients following autologous transplantation, further randomized prospective studies are required to evaluate the role of blood progenitor cell transplantation after high-dose treatment in multiple myeloma. Prognostical factors and future treatment modalities for myeloma are discussed.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.